Vaxcyte, Inc.
PCVXNasdaqCIK 1649094HealthcareFiscal year ends Dec 31
Reports and events: 101 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2023-09-0720:05 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-23-230628 |
| 2023-08-0820:12 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-039817 |
| 2023-08-0820:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-039777 |
| 2023-06-1520:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-23-167882 |
| 2023-05-0820:19 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-018835 |
| 2023-05-0820:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-018818 |
| 2023-04-2810:06 ET | DEF 14A | Proxy statement | 0001193125-23-123940 |
| 2023-04-2001:59 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-106984 |
| 2023-04-1711:36 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-102874 |
| 2023-03-0621:16 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-23-061401 |
| 2023-02-2722:09 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-050965 |
| 2023-02-2721:17 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-004654 |
| 2023-02-2721:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-004639 |
| 2022-12-2021:07 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-22-309137 |
| 2022-12-1221:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-22-302736 |
| 2022-11-0721:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-022628 |
| 2022-11-0721:07 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-022597 |
| 2022-10-2701:59 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-270039 |
| 2022-10-2412:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-267147 |
| 2022-08-0820:22 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-015552 |
| 2022-08-0820:02 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-015501 |
| 2022-06-0721:12 ET | 8-K | 5.07 Shareholder vote results | 0001193125-22-169367 |
| 2022-05-0920:19 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-008507 |
| 2022-05-0920:09 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000950170-22-008485 |
| 2022-04-2020:01 ET | DEF 14A | Proxy statementPeriod 2022-06-01 | 0001193125-22-111079 |
| 2022-04-1821:17 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-22-108155 |
| 2022-02-2821:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-002311 |
| 2022-02-2821:04 ET | 10-K | Annual reportPeriod 2021-12-31 | 0000950170-22-002281 |
| 2022-01-1322:16 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-008768 |
| 2021-11-1021:24 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-056215 |
| 2021-11-1021:06 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0001564590-21-056178 |
| 2021-10-2814:57 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-310735 |
| 2021-09-2020:35 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-277335 |
| 2021-08-1120:17 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-043448 |
| 2021-08-1120:02 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001564590-21-043419 |
| 2021-06-0320:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-21-181295 |
| 2021-05-1120:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-026535 |
| 2021-05-1120:01 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001564590-21-026529 |
| 2021-04-1420:06 ET | DEF 14A | Proxy statementPeriod 2021-06-02 | 0001193125-21-116258 |
| 2021-03-2920:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-016120 |
| 2021-03-2920:02 ET | 10-K | Annual reportPeriod 2020-12-31 | 0001564590-21-016110 |
| 2021-03-2523:59 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-092940 |
| 2021-01-2521:05 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-21-016229 |
| 2020-12-2213:15 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-20-323913 |
| 2020-11-1221:24 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-20-053599 |
| 2020-11-1221:03 ET | 10-Q | Quarterly reportPeriod 2020-09-30 | 0001564590-20-053540 |
| 2020-08-1220:24 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-20-039704 |
| 2020-08-1220:01 ET | 10-Q | Quarterly reportPeriod 2020-06-30 | 0001564590-20-039664 |
| 2020-06-1620:30 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-20-170425 |
| 2020-06-0810:31 ET | S-1/A | Registration statement, amended | 0001193125-20-162659 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.